Skip to main content

Patient Support Line 1-800-282-7630, Monday – Friday: 9 AM – 5 PM ET

Icon that says it’s not chemotherapy
KISQALI is a targeted treatment

KISQALI is not chemotherapyit's a pill you take that's called a targeted treatment, meaning it blocks, or interferes with, substances that play a role in cancer cell growth. Targeted therapies affect cancer cells, but can also affect healthy cells.

Menopausal status determines the hormone therapy you take with KISQALI because HR+, HER2- metastatic breast cancer (mBC) is fueled by hormones like estrogen

Premenopausal means that you are still producing estrogen from your ovaries, in addition to estrogen that is created in other tissues throughout the body
Illustration of woman pointing to ovaries and other tissues of the body that create estrogen text says estrogen is still being produced

Premenopausal women are given goserelin and a nonsteroidal aromatase inhibitor (NSAI) along with KISQALI

Illustration of 2 women. On the 1st woman the arrows point to ovaries. Text says goserelin stops the ovaries from making estrogen. On the 2nd woman arose point to cells text says the NSAI stops the creation of estrogen outside of the cancer cells.
 
Postmenopausal means that you are no longer producing estrogen from your ovaries
Illustration of woman pointing to ovaries text says no longer producing estrogen

Postmenopausal women are given an NSAI or fulvestrant along with KISQALI

Illustration of woman pointing to ovaries and cancer cells text says an NSAI or fulvestrant lowers the amount of estrogen that can bind to cancer cells.
See How KISQALI Works with an NSAI or Fulvestrant

To understand how KISQALI works with a nonsteroidal aromatase inhibitor (NSAI) (eg, letrozole or anastrozole) or fulvestrant, it's important to learn about the role that hormones/hormone receptors play in causing your type of cancer cells to grow and divide.

Important Safety Information

What is the most important information I should know about KISQALI ?

KISQALI may cause serious side effects, including:

Lung problems. KISQALI may cause severe or life-threatening inflammation of the lungs during treatment that may lead to death. Tell your health care provider right away if you have any new or...

Indications

KISQALI is a prescription medicine used to treat adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer that has gotten worse or has spread to other parts of the body (metastatic), in combination with:

  • an aromatase inhibitor as the first endocrine-based therapy; or...
Click or scroll to see IMPORTANT SAFETY INFORMATION AND APPROVED USE